Oculis Holding AG has randomized its first patient in PREDICT-1, a genotype-based registrational trial evaluating licaminlimab for dry eye disease (DED). The milestone marks a significant step toward potential approval of what the Zug, Switzerland-based biopharmaceutical company describes as a precision medicine approach to a condition affecting hundreds of millions of adults globally — and a condition increasingly targeted by functional ingredient suppliers and finished-formula brands.
Licaminlimab is a topical biologic candidate designed to address specific immunological pathways implicated in DED pathogenesis. The PREDICT-1 trial — an acronym for Personalized dRy Eye Disease Investigational Clinical Trial — stratifies participants by genotype, a design that positions the therapy closer to targeted biologics than to the broad-spectrum anti-inflammatory approaches common in both pharmaceutical and nutraceutical categories. Clinical endpoints, dosing parameters, and enrollment targets have not yet been disclosed in full by the company.
The dry eye category sits at an increasingly contested intersection of pharma, medical devices, and the functional nutrition market. Omega-3 fatty acids, particularly re-esterified triglyceride-form fish oil at clinically relevant doses, hold the strongest evidence base among dietary supplement interventions for DED, with multiple double-blind, placebo-controlled trials supporting tear film improvement as a clinical endpoint. Brands positioned in the ocular-health segment — including those leveraging astaxanthin, lutein, zeaxanthin, and phospholipid-bound DHA — will be watching the PREDICT-1 data closely, as precision stratification frameworks developed in the Rx space often migrate downstream into supplement and functional food positioning. Operators developing ocular-health formulations should note that a validated genotype-linked mechanism could raise the bar for structure-function claims in adjacent categories.
From a market context standpoint, the global dry eye therapeutics market is valued in the multi-billion dollar range, and consumer demand for proactive eye-health solutions has propelled the nutraceutical subcategory alongside it. Retail and e-commerce channels have seen meaningful growth in combination ocular supplements, with brands bundling omega-3s alongside carotenoids and vitamin D. The functional foods sector has been slower to penetrate ocular health specifically, though fortified beverages and softgels targeting screen-fatigue consumers represent a growth vector that ingredient suppliers are actively developing.
For nutraceutical operators, the Oculis announcement is less a direct competitive signal than a leading indicator of where clinical science — and eventually consumer education — is heading. A successful precision-medicine trial in DED could catalyze demand for companion diagnostic-style positioning across supplement categories, rewarding brands that invest in clinical substantiation and biomarker-linked dosing protocols now.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.